Track 10 of 14
Pulmonary Hypertension & Right Heart
Sotatercept (STELLAR/CADENCE), CTEPH, BPA and right-heart imaging.
Pulmonary hypertension treatment has been redefined by sotatercept — the first activin-signaling inhibitor approved for PAH after STELLAR demonstrated dramatic 6-minute walk gains, with CADENCE extending the data. The track covers risk-stratified upfront triple therapy, the modern role of macitentan/tadalafil combinations (A DUE), and the expanding indications for balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy in CTEPH. Right-ventricular imaging and assessment receive dedicated programming, including CMR-derived RV strain, exercise hemodynamics, and the emerging Group 2 PH (HFpEF) phenotype with sotatercept readouts (HYPERION, ZENITH).
Focus areas
- Sotatercept in PAH: STELLAR, CADENCE, ZENITH (Group 2)
- Risk-stratified upfront combination therapy
- CTEPH: balloon pulmonary angioplasty and PEA selection
- Right ventricular imaging: CMR strain and 4D flow
- Exercise hemodynamics and unmasking PH
- Group 2 PH (HFpEF) and Group 3 PH (lung disease)
- Lung transplantation referral in advanced PH